The financing was led by existing investors Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund, alongside continued support from Finnish investors including the Jenny and Antti Wihuri Foundation, Innovestor, and the Gösta Serlachius Fine Arts Foundation.

“This financing represents another important milestone for Aplagon as we continue to build momentum around APAC and its potential across a broad range of serious thrombo-inflammatory diseases. The financing supports the expansion of our clinical development plans in Phase 2 in Europe for AVF, having recently filed our CTA with the EMA. The continued backing from our experienced healthcare investors validates both the strength of our clinical progress and the growing recognition of APAC’s differentiated mechanism of action that overcomes the limits of current treatments,” says Aki Prihti, CEO at Aplagon.

The company previously announced here that the first patient had been dosed in its Phase 2a ‘HEALING’ clinical trial in peripheral arterial occlusive disease (PAOD) leading to chronic limb threatening ischemia (CLTI).